KyrgyzstanTuberculosis profile
Population  2016 6 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.43 (0.42–0.44) 7.2 (7–7.3)
Mortality (HIV+TB only) 0.059 (0.046–0.074) 0.99 (0.77–1.2)
Incidence  (includes HIV+TB) 8.7 (7.7–9.6) 145 (130–162)
Incidence (HIV+TB only) 0.28 (0.25–0.32) 4.8 (4.2–5.4)
Incidence (MDR/RR-TB)** 4.8 (4–5.5) 80 (68–92)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.48 (0.43–0.54) 3.2 (2.9–3.6) 3.7 (3.3–4.1)
Males 0.55 (0.49–0.61) 4.4 (3.9–4.9) 4.9 (4.4–5.5)
Total 1 (0.92–1.1) 7.6 (6.8–8.5) 8.7 (7.7–9.6)
TB case notifications, 2016  
Total cases notified 7 995
Total new and relapse 7 026
          - % tested with rapid diagnostics at time of diagnosis 36%
          - % with known HIV status 89%
          - % pulmonary 78%
          - % bacteriologically confirmed among pulmonary 58%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 81% (73–91)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.05–0.06)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 210 3%
          - on antiretroviral therapy 144 69%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2 500
(2 400–2 600)
Estimated % of TB cases with MDR/RR-TB 27% (25–29) 60% (57–63)  
% notified tested for rifampicin resistance 42% 47% 3 489
MDR/RR-TB cases tested for resistance to second-line drugs   415
Laboratory-confirmed cases MDR/RR-TB: 1 236, XDR-TB: 73
Patients started on treatment **** MDR/RR-TB: 1 216, XDR-TB: 67
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 82% 6 139
Previously treated cases, excluding relapse, registered in 2015 66% 547
HIV-positive TB cases registered in 2015 61% 151
MDR/RR-TB cases started on second-line treatment in 2014 56% 1 157
XDR-TB cases started on second-line treatment in 2014 16% 32
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 40%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
75% (69–83)
TB financing, 2017  
National TB budget (US$ millions) 25
Funding source: 47% domestic, 52% international, 1% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data